PURPOSE: To evaluate the downstaging efficacy of yttrium-90 radioembolization (Ytt-90)-associated with chemotherapy and the results of surgery for initially unresectable huge intrahepatic cholangiocarcinoma (ICC). METHODS: Between January 2008 and October 2013, unresectable ICC were treated with chemotherapy and Ytt-90. Patients with unique tumors localized to noncirrhotic livers and without extrahepatic metastasis were considered to be potentially resectable and were evaluated every 2 months for possible secondary resection. RESULTS: Forty-five patients were treated for unresectable ICCs; ten had potentially resectable tumors, and eight underwent surgery. Initial unresectability was due to the involvement of the hepatic veins or portal vein of the future liver remnant in seven and one cases, respectively. Preoperative treatment induced significant decreases in tumor volume (295 vs. 168 ml, p = 0.02) and allowed for R0 resection in all cases. Three patients (37.5 %) had Clavien-Dindo grade three or higher complications, including two postoperative deaths. The median follow-ups were 15.6 [range 4-40.7] months after medical treatment initiation and 7.2 [0.13-36.4] months after surgery. At the end of the study period, five patients were still alive, with one patient still alive 40 months after medical treatment initiation (36.4 months after surgery); two patients experienced recurrences. CONCLUSIONS: For initially unresectable huge ICCs, chemotherapy with Ytt-90 radioembolization is an effective downstaging method that allows for secondary resectability.
PURPOSE: To evaluate the downstaging efficacy of yttrium-90 radioembolization (Ytt-90)-associated with chemotherapy and the results of surgery for initially unresectable huge intrahepatic cholangiocarcinoma (ICC). METHODS: Between January 2008 and October 2013, unresectable ICC were treated with chemotherapy and Ytt-90. Patients with unique tumors localized to noncirrhotic livers and without extrahepatic metastasis were considered to be potentially resectable and were evaluated every 2 months for possible secondary resection. RESULTS: Forty-five patients were treated for unresectable ICCs; ten had potentially resectable tumors, and eight underwent surgery. Initial unresectability was due to the involvement of the hepatic veins or portal vein of the future liver remnant in seven and one cases, respectively. Preoperative treatment induced significant decreases in tumor volume (295 vs. 168 ml, p = 0.02) and allowed for R0 resection in all cases. Three patients (37.5 %) had Clavien-Dindo grade three or higher complications, including two postoperative deaths. The median follow-ups were 15.6 [range 4-40.7] months after medical treatment initiation and 7.2 [0.13-36.4] months after surgery. At the end of the study period, five patients were still alive, with one patient still alive 40 months after medical treatment initiation (36.4 months after surgery); two patients experienced recurrences. CONCLUSIONS: For initially unresectable huge ICCs, chemotherapy with Ytt-90 radioembolization is an effective downstaging method that allows for secondary resectability.
Authors: Michel Rayar; Giovanni Battista Levi Sandri; Marc Blondeau; Mohamed Lakehal; Véronique Desfourneaux; Laurent Sulpice; Bernard Meunier; Karim Boudjema Journal: Transl Gastroenterol Hepatol Date: 2018-05-02
Authors: Giuseppe Maria Ettorre; Giovanni Battista Levi Sandri; Andrea Laurenzi; Marco Colasanti; Roberto Luca Meniconi; Raffaella Lionetti; Roberto Santoro; Pasquale Lepiane; Rosa Sciuto; Giuseppe Pizzi; Roberto Cianni; Rita Golfieri; Gianpiero D'Offizi; Adriano M Pellicelli; Mario Antonini; Giovanni Vennarecci Journal: World J Surg Date: 2017-01 Impact factor: 3.352
Authors: Anna Maria Ierardi; Salvatore Alessio Angileri; Francesca Patella; Silvia Panella; Natalie Lucchina; Elena N Petre; Antonio Pinto; Giuseppe Franceschelli; Gianpaolo Carrafiello; Gianpaolo Cornalba; Constantinos T Sofocleous Journal: Med Oncol Date: 2016-12-22 Impact factor: 3.064
Authors: Pietro Addeo; Issam Jedidi; Andrea Locicero; François Faitot; Constantin Oncioiu; Alina Onea; Philippe Bachellier Journal: J Gastrointest Surg Date: 2018-11-26 Impact factor: 3.452